Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

Sanofi (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active approach to acquisitions in the near term. The ...

Deutsche Bank has upgraded Sanofi (NASDAQ:SNY) to hold from sell, citing the company's Q4 earnings report. The investment ...

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

Oppenheimer initiated coverage on Alumis Inc (NASDAQ:ALMS) with an Outperform rating and a price target of $32.00. The firm's analysts highlighted the biopharmaceutical company's focus on developing ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio. The expansion is fueled by increased ...

Oppenheimer launched its coverage of Alumis (NASDAQ:ALMS) with an Outperform recommendation and a 12–18-month price target of ...

SOUTH SAN FRANCISCO - Cytokinetics , Incorporated (NASDAQ:CYTK), a $5.7 billion biopharmaceutical company, has announced the awarding of $100,000 in grants to five patient advocacy organizations ...

Investing.com - European stock markets rose Thursday, as investors digested a deluge of corporate earnings ahead of the European Central Bank’s latest policy decision and the release of regional ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...